Journal
VACCINE
Volume 35, Issue 46, Pages 6290-6296Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2017.09.078
Keywords
Tetanus; Vaccination; Autoimmune disease; Myasthenia gravis; Immunosuppression; Antibodies
Categories
Funding
- project Myasterix [602420]
Ask authors/readers for more resources
Objective: To investigate the humoral immune response to and safety of a tetanus revaccination in patients with myasthenia gravis or Lambert-Eaton myasthenic syndrome. Methods: A tetanus revaccination was administered to 66 patients. Before and 4 weeks after revaccination a blood sample and clinical outcome scores were obtained. Anti-tetanus IgG total, IgG1 and IgG4 titres were measured with an ELISA and disease-specific antibody titres (AChR, MuSK or VGCC) with a radio-immunoprecipitation assay. A historic healthy control group was used for comparing tetanus antibody titres with that of our patients. A placebo (saline) vaccination group was used to investigate the variability of clinical outcome scores with a 4 weeks interval. Results: In 60 of 65 patients, a significant increase of the anti-tetanus antibody response was measured. Thymectomy did not have an impact on this responsiveness. Patients with immunosuppressive medication had a significantly lower pre and post titre compared to healthy controls, but their response was still significant. The titres of disease-specific antibodies were unchanged 4 weeks after revaccination. The clinical outcome scores showed no exacerbation of symptoms of the disease. Conclusion: A tetanus revaccination in patients with myasthenia gravis or Lambert-Eaton myasthenic syndrome is safe and induces a significant immune response, irrespectively of their immunosuppressive medication. We observed neither immunological nor clinical relevant exacerbations associated with the tetanus revaccination. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available